804 related articles for article (PubMed ID: 29480353)
1. Multiplex immunoassay measurement of amyloid-β
Vogelgsang J; Shahpasand-Kroner H; Vogelgsang R; Streit F; Vukovich R; Wiltfang J
Exp Brain Res; 2018 May; 236(5):1241-1250. PubMed ID: 29480353
[TBL] [Abstract][Full Text] [Related]
2. A two-step immunoassay for the simultaneous assessment of Aβ38, Aβ40 and Aβ42 in human blood plasma supports the Aβ42/Aβ40 ratio as a promising biomarker candidate of Alzheimer's disease.
Shahpasand-Kroner H; Klafki HW; Bauer C; Schuchhardt J; Hüttenrauch M; Stazi M; Bouter C; Wirths O; Vogelgsang J; Wiltfang J
Alzheimers Res Ther; 2018 Dec; 10(1):121. PubMed ID: 30526652
[TBL] [Abstract][Full Text] [Related]
3. Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice.
Sauvée M; DidierLaurent G; Latarche C; Escanyé MC; Olivier JL; Malaplate-Armand C
J Alzheimers Dis; 2014; 41(2):377-86. PubMed ID: 24614902
[TBL] [Abstract][Full Text] [Related]
4. Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study.
de Wolf F; Ghanbari M; Licher S; McRae-McKee K; Gras L; Weverling GJ; Wermeling P; Sedaghat S; Ikram MK; Waziry R; Koudstaal W; Klap J; Kostense S; Hofman A; Anderson R; Goudsmit J; Ikram MA
Brain; 2020 Apr; 143(4):1220-1232. PubMed ID: 32206776
[TBL] [Abstract][Full Text] [Related]
5. The cerebrospinal fluid amyloid beta42/40 ratio in the differentiation of Alzheimer's disease from non-Alzheimer's dementia.
Spies PE; Slats D; Sjögren JM; Kremer BP; Verhey FR; Rikkert MG; Verbeek MM
Curr Alzheimer Res; 2010 Aug; 7(5):470-6. PubMed ID: 20043812
[TBL] [Abstract][Full Text] [Related]
6. Elevation of the Plasma Aβ40/Aβ42 Ratio as a Diagnostic Marker of Sporadic Early-Onset Alzheimer's Disease.
Kim HJ; Park KW; Kim TE; Im JY; Shin HS; Kim S; Lee DH; Ye BS; Kim JH; Kim EJ; Park KH; Han HJ; Jeong JH; Choi SH; Park SA
J Alzheimers Dis; 2015; 48(4):1043-50. PubMed ID: 26444752
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.
Bousiges O; Cretin B; Lavaux T; Philippi N; Jung B; Hezard S; Heitz C; Demuynck C; Gabel A; Martin-Hunyadi C; Blanc F
J Alzheimers Dis; 2016; 51(4):1069-83. PubMed ID: 26923009
[TBL] [Abstract][Full Text] [Related]
8. The relationship of plasma Aβ levels to dementia in aging individuals with mild cognitive impairment.
Fei M; Jianghua W; Rujuan M; Wei Z; Qian W
J Neurol Sci; 2011 Jun; 305(1-2):92-6. PubMed ID: 21440911
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of selenium, redox status and their association with plasma amyloid/tau in Alzheimer's disease.
Krishnan S; Rani P
Biol Trace Elem Res; 2014 May; 158(2):158-65. PubMed ID: 24682919
[TBL] [Abstract][Full Text] [Related]
10. Evolution of Abeta42 and Abeta40 levels and Abeta42/Abeta40 ratio in plasma during progression of Alzheimer's disease: a multicenter assessment.
Blennow K; De Meyer G; Hansson O; Minthon L; Wallin A; Zetterberg H; Lewczuk P; Vanderstichele H; Vanmechelen E; Kornhuber J; Wiltfang J; ; Heuser I; Maier W; Luckhaus C; Rüther E; Hüll M; Jahn H; Gertz HJ; Frölich L; Hampel H; Pernetzki R
J Nutr Health Aging; 2009 Mar; 13(3):205-8. PubMed ID: 19262954
[TBL] [Abstract][Full Text] [Related]
11. Plasma Amyloid Concentration in Alzheimer's Disease: Performance of a High-Throughput Amyloid Assay in Distinguishing Alzheimer's Disease Cases from Controls.
Feinkohl I; Schipke CG; Kruppa J; Menne F; Winterer G; Pischon T; Peters O
J Alzheimers Dis; 2020; 74(4):1285-1294. PubMed ID: 32176645
[TBL] [Abstract][Full Text] [Related]
12. Alzheimer's cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans : CSF AD biomarkers measured by Lumipulse in Koreans.
Moon S; Kim S; Mankhong S; Choi SH; Vandijck M; Kostanjevecki V; Jeong JH; Yoon SJ; Park KW; Kim EJ; Yoon B; Kim HJ; Jang JW; Hong JY; Park DH; Shaw LM; Kang JH
Alzheimers Res Ther; 2021 Jan; 13(1):22. PubMed ID: 33436035
[TBL] [Abstract][Full Text] [Related]
13. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease.
Mehta PD; Pirttilä T; Mehta SP; Sersen EA; Aisen PS; Wisniewski HM
Arch Neurol; 2000 Jan; 57(1):100-5. PubMed ID: 10634455
[TBL] [Abstract][Full Text] [Related]
14. Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer's disease.
Wang MJ; Yi S; Han JY; Park SY; Jang JW; Chun IK; Kim SE; Lee BS; Kim GJ; Yu JS; Lim K; Kang SM; Park YH; Youn YC; An SSA; Kim S
Alzheimers Res Ther; 2017 Dec; 9(1):98. PubMed ID: 29246249
[TBL] [Abstract][Full Text] [Related]
15. Distinction between mild cognitive impairment and Alzheimer's disease by CSF amyloid β40 and β42, and protein-conjugated acrolein.
Mizoi M; Yoshida M; Saiki R; Waragai M; Uemura K; Akatsu H; Kashiwagi K; Igarashi K
Clin Chim Acta; 2014 Mar; 430():150-5. PubMed ID: 24508996
[TBL] [Abstract][Full Text] [Related]
16. Chemically treated plasma Aβ is a potential blood-based biomarker for screening cerebral amyloid deposition.
Park JC; Han SH; Cho HJ; Byun MS; Yi D; Choe YM; Kang S; Jung ES; Won SJ; Kim EH; Kim YK; Lee DY; Mook-Jung I
Alzheimers Res Ther; 2017 Mar; 9(1):20. PubMed ID: 28330509
[TBL] [Abstract][Full Text] [Related]
17. Plasma concentrations of free amyloid β cannot predict the development of Alzheimer's disease.
Lövheim H; Elgh F; Johansson A; Zetterberg H; Blennow K; Hallmans G; Eriksson S
Alzheimers Dement; 2017 Jul; 13(7):778-782. PubMed ID: 28073031
[TBL] [Abstract][Full Text] [Related]
18. Plasma Amyloid-β (Aβ42) Correlates with Cerebrospinal Fluid Aβ42 in Alzheimer's Disease.
Teunissen CE; Chiu MJ; Yang CC; Yang SY; Scheltens P; Zetterberg H; Blennow K
J Alzheimers Dis; 2018; 62(4):1857-1863. PubMed ID: 29614646
[TBL] [Abstract][Full Text] [Related]
19. Amyloid beta protein and tau in cerebrospinal fluid and plasma as biomarkers for dementia: a review of recent literature.
Frankfort SV; Tulner LR; van Campen JP; Verbeek MM; Jansen RW; Beijnen JH
Curr Clin Pharmacol; 2008 May; 3(2):123-31. PubMed ID: 18700307
[TBL] [Abstract][Full Text] [Related]
20. Antemortem CSF A
Baiardi S; Abu-Rumeileh S; Rossi M; Zenesini C; Bartoletti-Stella A; Polischi B; Capellari S; Parchi P
Ann Clin Transl Neurol; 2019 Feb; 6(2):263-273. PubMed ID: 30847359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
